Solid Biosciences
Advancing gene therapy candidates for Duchenne and other rare neuromuscular and cardiac diseases.
Something off on this page? Send us feedback.
Profile
Develops investigational gene therapies led by SGT-003 for Duchenne, with additional programs for Friedreich's ataxia, CPVT, and genetic cardiomyopathies. The business has no approved products or product-sales revenue, so progress depends on clinical trials, regulatory approvals, manufacturing partners, and financing.
Advances a clinical-stage gene therapy pipeline for rare neuromuscular and cardiac diseases. Lead program SGT-003 targets Duchenne muscular dystrophy, while SGT-212, SGT-501, SGT-601, and earlier cardiac assets extend the platform into Friedreich's ataxia, CPVT, and genetic cardiomyopathies.
Built from a Duchenne patient-origin story, the company now operates from a single reportable segment and remains centered on research and development rather than product sales. Work is anchored in Massachusetts, while SGT-003 clinical execution reaches a late-stage multi-country trial.
Execution depends on trial enrollment and results, biologics approvals, manufacturing scale-up through third parties, and access to capital. Competition includes approved Duchenne therapies and investigational gene-therapy or rare-disease programs across its target conditions.
Company facts
Key statistics
Year to date +79.4% · Average volume (30d) 925.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 27, 2026 | Cantor Fitzgerald | Reiterate | Overweight | $16 | $26 |
| Aug 21, 2026 | Truist Financial | Target | $20 | ||
| May 13, 2026 | Wedbush | Reiterate | Outperform | $16 | |
| May 13, 2026 | Piper Sandler | Reiterate | Overweight | $20 | $18 |
| Dec 4, 2025 | Needham | Target | $16 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.46 | −$0.38 | +17.8% | — | — | — | −3.67% |
| May 12, 2026Q1 FY26 | −$0.40 | −$0.52 | −30.0% | — | — | — | −4.40% |
| Mar 19, 2026Q4 FY25 | −$0.51 | −$0.50 | +2.0% | — | — | — | −1.26% |
| Nov 3, 2025Q3 FY25 | −$0.42 | −$0.48 | −14.3% | — | — | — | −15.19% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$407.0K | −$386.0K | $0 | $0 | −$395.0K | $0 | |
| Operating income | −$40.1M | −$41.7M | −$48.1M | −$49.4M | −$57.3M | −$57.4M | |
| Net income | −$39.3M | −$39.5M | −$45.8M | −$49.8M | −$56.7M | −$54.8M | |
| Diluted EPS | −$0.59 | −$0.42 | −$0.48 | −$0.53 | −$0.52 | −$0.38 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $13.6M · FY22 $8.1M · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $377.7M · Total debt $20.2M · Total assets $420.6M · Shareholders' equity $374.1M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 98.45M · Float 78.20M · 79.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | 12.05M | 11.20% | 13D | Aug 14, 2026 |
| Ra Capital Management, L.P. | 12.04M | 12.23% | 13F | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 9.81M | 9.96% | 13F | Aug 14, 2026 |
| Invus Public Equities, L.P. | 8.70M | 8.70% | 13G | May 5, 2026 |
| BCLS II Investco, LP | 8.60M | 8.80% | 13D | Mar 10, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 18, 2026 | Kevin Tan | officer: CFO & Treasurer | −5,404 | $5.82 |
| Feb 18, 2026 | Gabriel Brooks | officer: Chief Medical Officer | 0 | |
| Feb 18, 2026 | David T. Howton | officer: Chief Operating Officer | −7,469 | $5.82 |
| Feb 18, 2026 | Paul Herzich | officer: Chief Technology Officer | −3,616 | $5.82 |
| Feb 18, 2026 | Ilan Ganot | director | −2,658 | $5.82 |
Peers
- Sarepta Therapeutics
Approved DMD gene therapy and exon-skipping portfolio
- REGENXBIO
Late-stage Duchenne microdystrophin gene therapy
- Capricor Therapeutics
Late-stage DMD cell therapy with FDA review
- Lexeo Therapeutics
FA cardiomyopathy gene therapy rival
- Edgewise Therapeutics
Muscle-preservation therapy across Duchenne and Becker
- Dyne Therapeutics
DMD exon 51 program with BLA submitted
- Novartis (ADR)
Owner of Avidity's late-stage neuromuscular RNA assets
- Biogen
Commercial FA therapy and pediatric expansion study
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Solid Biosciences | $9.77 | −0.10% | $961.9M | — | — | — | — |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| REGENXBIO | $9.65 | −0.21% | $499.4M | — | — | 2.9 | +405.7% |
| Capricor Therapeutics | $9.64 | +0.41% | $551.5M | — | — | — | — |
| Lexeo Therapeutics | $4.77 | −1.95% | $381.6M | — | — | — | — |
| Edgewise Therapeutics | $42.76 | −0.04% | $4.60B | — | — | — | — |
| Dyne Therapeutics | $25.07 | −0.04% | $4.68B | — | — | — | — |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| Median | 30.9 | 16.5 | 3.1 | +2.2% |